Novo Nordisk: 2024 Earnings Review
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Big pharma steps up push for taxpayer-funded weight-loss drugs
Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...
Rolling Out16h
The weight loss drug dilemma no one wants to talk about
GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...
Two U.S. senators slammed an S.F. telehealth company’s Super Bowl ad. Here’s why
A San Francisco online health company that recently faced local backlash over its donation to President Donald Trump’s inauguration is now in hot water over a Super Bowl ad. Hims & Hers, a telehealth ...
Super Bowl ad on weight loss drugs calls out America’s ‘broken’ health care; Senators express concern
Super Bowl commercial, telehealth company Hims & Hers takes aim at the obesity epidemic and critiques America's healthcare ...